Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma

Leukemia & Lymphoma
Ehsan MalekMuzaffar H Qazilbash

Abstract

High-dose melphalan (HDM) followed by autologous hematopoietic cell transplantation (auto-HCT) remains the standard-of-care therapy for multiple myeloma (MM) even with the availability of proteasome inhibitors and immunomodulatory drugs. Gastrointestinal (GI) toxicity is the main cause of morbidity after HDM. Amifostine, a cytoprotective agent, may reduce HDM-associated GI toxicity. We conducted a case control study comparing HDM + auto-HCT with or without amifostine for MM patients. One hundred and seven patients treated at University Hospitals Cleveland Medical Center who received pre-transplant amifostine were compared to 114 patients treated at MD Anderson Cancer Center without use of this agent. Amifostine 740 mg/m2 was administered as a bolus infusion at 24 h and 15 min before HDM. Patients' characteristics were similar in both the groups. Amifostine therapy was well tolerated without any significant adverse effects. Grade II or greater oral mucositis (27.1% vs 47.4%; p = .002), nausea (31.8% vs. 86.0%; p = .0001), vomiting (18.7% vs. 52.6%; p = .0001) and diarrhea (56.1% vs. 72.7%; p = .006) occurred less frequently in the amifostine-treated group. There was no discernable effect of amifostine on engraftment, progression...Continue Reading

References

Jun 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LazarusP Coccia
Jan 1, 1982·British Journal of Cancer·J PritchardJ Graham-Pole
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L DouayN C Gorin
Jan 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R L Capizzi
Jan 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R M Bukowski
Apr 1, 1997·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·J A Foster-Nora, R Siden
Jul 6, 2000·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·C A De SouzaE Damasio
Oct 3, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D M BrizelR Sauer
Mar 10, 2004·Cancer Chemotherapy and Pharmacology·Philippe MougenotFrançoise Bressolle
May 20, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Stuart L GoldbergStephanie Hamarman
Jun 19, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·G L PhillipsN Flomenberg
Jul 28, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I DimopoulouM A Dimopoulos
Dec 17, 2004·The New England Journal of Medicine·Ricardo SpielbergerChristos Emmanouilides
Mar 31, 2005·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Samuel VokurkaLubica Misaniová
Dec 6, 2005·Contemporary Clinical Trials·Pingfu FuHeping Zhang
Feb 28, 2006·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Samuel VokurkaLubica Misaniová
Aug 10, 2006·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Pamela HorsleyJohn Bashford
May 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hillard M LazarusGeoffrey P Herzig
May 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Benjamin D SmithThomas A Buchholz
Mar 2, 2011·Bone Marrow Transplantation·P MoreauJ L Harousseau
Aug 28, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ulas D BayraktarStefan O Ciurea
Mar 13, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ajay K NookaEdmund K Waller
Mar 13, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Tomer M MarkRuben Niesvizky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.